Salud financiera de hoja de balance de Citius Pharmaceuticals
Salud financiera controles de criterios 6/6
Citius Pharmaceuticals has a total shareholder equity of $85.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $97.4M and $12.1M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$20.35m |
| Patrimonio | US$85.33m |
| Total pasivo | US$12.07m |
| Activos totales | US$97.40m |
Actualizaciones recientes sobre salud financiera
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($28.2M) de CTXR superan a sus pasivos a corto plazo ($5.6M).
Pasivo a largo plazo: Los activos a corto plazo de CTXR ($28.2M) superan a sus pasivos a largo plazo ($6.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CTXR is debt free.
Reducción de la deuda: CTXR has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CTXR tiene suficiente cash runway para 8 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.
Pronóstico de cash runway: Se prevé que CTXR disponga de suficiente cash runway para 8 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.